JP6348900B2 - 凝固因子ｘｉおよび／またはその活性化形態である因子ｘｉａに結合しうる抗体ならびにその用途 - Google Patents

凝固因子ｘｉおよび／またはその活性化形態である因子ｘｉａに結合しうる抗体ならびにその用途 Download PDF

Info

Publication number
JP6348900B2
JP6348900B2 JP2015510818A JP2015510818A JP6348900B2 JP 6348900 B2 JP6348900 B2 JP 6348900B2 JP 2015510818 A JP2015510818 A JP 2015510818A JP 2015510818 A JP2015510818 A JP 2015510818A JP 6348900 B2 JP6348900 B2 JP 6348900B2
Authority
JP
Japan
Prior art keywords
antibody
antibodies
seq
fxia
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015510818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517305A (ja
JP2015517305A5 (enExample
Inventor
ビルメン，アンドレアス
シユトラスバーガー，ユリア
デイツトマー，フランク
シユトレラート，ミヒヤエル
ブーフミユーラー，アンヤ
グルドジンスカ−ゴーベル，ヨアンナ
フイネルン，リカルダ
シエーフアー，マルテイナ
ゲルデス，クリストフ
ヨリツセン，ハンナア
イタクラ，アサコ
ワイ・レウン，フイルベルタ
タツカー，エリツク
Original Assignee
バイエル ファーマ アクチエンゲゼルシャフト
バイエル ファーマ アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイエル ファーマ アクチエンゲゼルシャフト, バイエル ファーマ アクチエンゲゼルシャフト filed Critical バイエル ファーマ アクチエンゲゼルシャフト
Publication of JP2015517305A publication Critical patent/JP2015517305A/ja
Publication of JP2015517305A5 publication Critical patent/JP2015517305A5/ja
Application granted granted Critical
Publication of JP6348900B2 publication Critical patent/JP6348900B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2015510818A 2012-05-10 2013-05-08 凝固因子ｘｉおよび／またはその活性化形態である因子ｘｉａに結合しうる抗体ならびにその用途 Active JP6348900B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP12167438.6 2012-05-10
EP12167438 2012-05-10
EP12181697.9 2012-08-24
EP12181697 2012-08-24
EP13150361.7 2013-01-07
EP13150361 2013-01-07
US201361817675P 2013-04-30 2013-04-30
US61/817,675 2013-04-30
PCT/EP2013/059618 WO2013167669A1 (en) 2012-05-10 2013-05-08 Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018106275A Division JP2018148920A (ja) 2012-05-10 2018-06-01 凝固因子ｘｉおよび／またはその活性化形態である因子ｘｉａに結合しうる抗体ならびにその用途

Publications (3)

Publication Number Publication Date
JP2015517305A JP2015517305A (ja) 2015-06-22
JP2015517305A5 JP2015517305A5 (enExample) 2016-06-23
JP6348900B2 true JP6348900B2 (ja) 2018-06-27

Family

ID=49550177

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015510818A Active JP6348900B2 (ja) 2012-05-10 2013-05-08 凝固因子ｘｉおよび／またはその活性化形態である因子ｘｉａに結合しうる抗体ならびにその用途
JP2018106275A Pending JP2018148920A (ja) 2012-05-10 2018-06-01 凝固因子ｘｉおよび／またはその活性化形態である因子ｘｉａに結合しうる抗体ならびにその用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018106275A Pending JP2018148920A (ja) 2012-05-10 2018-06-01 凝固因子ｘｉおよび／またはその活性化形態である因子ｘｉａに結合しうる抗体ならびにその用途

Country Status (24)

Country Link
US (4) US9783614B2 (enExample)
EP (2) EP2847228B1 (enExample)
JP (2) JP6348900B2 (enExample)
KR (1) KR102060376B1 (enExample)
CN (1) CN104684932B (enExample)
AR (1) AR091024A1 (enExample)
AU (2) AU2013258043B2 (enExample)
BR (1) BR112014027952B1 (enExample)
CA (1) CA2872926C (enExample)
DK (1) DK2847228T3 (enExample)
ES (1) ES2698950T3 (enExample)
HR (1) HRP20181680T1 (enExample)
HU (1) HUE040580T2 (enExample)
IL (1) IL235238B (enExample)
LT (1) LT2847228T (enExample)
MX (1) MX362454B (enExample)
NZ (1) NZ701121A (enExample)
PL (1) PL2847228T3 (enExample)
RS (1) RS57889B1 (enExample)
SG (2) SG10201609322QA (enExample)
SI (1) SI2847228T1 (enExample)
TW (2) TWI631140B (enExample)
WO (1) WO2013167669A1 (enExample)
ZA (1) ZA201407784B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2705851C (en) 2007-11-21 2016-11-01 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
AU2009335643B2 (en) 2008-12-18 2014-05-29 Oregon Health & Science University Anti-fXI antibodies and methods of use
IN2014CN02805A (enExample) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
IN2014CN02806A (enExample) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
LT2766346T (lt) 2011-10-14 2017-06-12 Bristol-Myers Squibb Company Pakeistieji tetrahidroizochinolino junginiai, kaip faktoriaus xia inhibitoriai
US9783614B2 (en) 2012-05-10 2017-10-10 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof
HRP20180465T1 (hr) 2012-10-12 2018-05-04 Bristol-Myers Squibb Company Kristalni oblici inhibitora faktora xia
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
JP6479763B2 (ja) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
NO2760821T3 (enExample) 2014-01-31 2018-03-10
JP6505727B2 (ja) 2014-01-31 2019-04-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環
TW201613977A (en) 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA201790336A1 (ru) 2014-08-07 2017-06-30 Новартис Аг Антитела к ангиопоэтинподобному белку 4 и способы применения
JP6526796B2 (ja) 2014-09-04 2019-06-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｆｘｉａ阻害剤であるジアミドマクロ環
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
CA2972800A1 (en) 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
JOP20160131B1 (ar) * 2015-06-26 2022-03-14 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3325516B1 (en) 2015-07-21 2021-12-15 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor xiia
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
US10053515B2 (en) 2016-01-22 2018-08-21 Merck Sharp & Dohme Corp. Anti-coagulation factor XI antibodies
KR102448456B1 (ko) * 2016-03-23 2022-09-28 프로틱스 비브이 인자 xi의 활성 부위에 대한 모노클로날 항체 및 이의 용도
JP7103950B2 (ja) 2016-04-22 2022-07-20 アクセレロン ファーマ インコーポレーテッド Ａｌｋ７結合性タンパク質及びその使用
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
EA201892716A1 (ru) 2016-06-14 2019-05-31 Мерк Шарп И Доум Корп. Антитела к фактору свертывания xi
AU2017329645A1 (en) * 2016-09-20 2019-04-04 Aronora Inc. Novel antibodies against factor XI and uses thereof
WO2018089248A2 (en) * 2016-11-02 2018-05-17 Tucker Erik L E-we thrombin analog and fibrinolytic combination
CN118320078A (zh) * 2016-12-23 2024-07-12 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
KR102616666B1 (ko) * 2016-12-23 2023-12-27 노파르티스 아게 인자 xi 항체 및 사용 방법
PT3570882T (pt) * 2017-01-19 2022-01-11 Bayer Pharma AG Nova formulação estável para anticorpos fxia
US11958911B2 (en) 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
CN108409863B (zh) * 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
EP3713965A1 (en) 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
WO2020008022A1 (en) * 2018-07-05 2020-01-09 Bayer Aktiengesellschaft METHOD FOR THE PRODUCTION OF FREEZE-DRIED PELLETS COMPRISING AN ANTI-COAGULATION FACTOR XIa (FXIa) ANTIBODY
PE20211399A1 (es) * 2018-08-01 2021-07-27 Novo Nordisk As Anticuerpos procoagulantes mejorados
JP7152682B2 (ja) 2018-08-07 2022-10-13 日本電信電話株式会社 光伝送システム及び伝送モード選択方法
CN113227150B (zh) * 2018-08-09 2023-07-28 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
EP3852820B1 (en) * 2018-09-17 2024-11-20 Board of Regents, The University of Texas System Compositions and methods for treating bone injury
WO2020089380A1 (en) 2018-10-31 2020-05-07 Bayer Aktiengesellschaft REVERSAL AGENTS FOR NEUTRALIZING THE THERAPEUTIC ACTIVITY OF ANTI-FXIa ANTIBODIES
US12703762B2 (en) 2018-12-18 2026-08-11 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
AU2020211905A1 (en) 2019-01-21 2021-08-05 Aronora Inc. Novel humanized antibodies against factor XI having anti-thrombotic and anti-inflammatory effects and uses thereof
EP3957652A4 (en) 2019-04-16 2023-06-21 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-fxi/fxia antibody and use thereof
CN110423278B (zh) 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
BR112022026533A2 (pt) * 2020-07-02 2023-01-17 Beijing Tuo Jie Biopharmaceutical Co Ltd Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo
EP4644426A1 (en) * 2022-12-30 2025-11-05 Gan & Lee Pharmaceuticals Co., Ltd. Antibody against coagulation factor xi and/or activated form factor xia thereof, and use thereof
CN119454938B (zh) * 2024-11-15 2025-07-25 广州骐骥生物科技有限公司 一种枸橼酸透析浓缩液及其制备方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
DE4319041A1 (de) 1992-10-23 1994-04-28 Bayer Ag Trisubstituierte Biphenyle
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US20030235587A1 (en) 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
ATE431347T1 (de) 1996-10-14 2009-05-15 Bayer Healthcare Ag Neue heterocyclylmethyl-substituierte pyrazolderivate und ihre verwendung in der behandlung von herz-kreislauf-erkrankungen
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
WO2000007626A1 (en) 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
US20080219998A1 (en) 2001-12-07 2008-09-11 Andras Gruber Anti-Thrombotic Agents
US20080138837A1 (en) 2004-07-19 2008-06-12 Robert Greenfield Methods and kits for detecting and measuring ADAMTS13/FXI complexes
US7270976B2 (en) 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7279513B2 (en) 2004-11-19 2007-10-09 Nalco Company Preparation of neutralized ethylene-acrylic acid polymer dispersions and use in printing media for improvement of digital toner adhesion
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
CA2661023C (en) 2006-08-18 2017-08-15 Novartis Ag Prlr-specific antibody and uses thereof
JP2010526066A (ja) 2007-04-23 2010-07-29 シェーリング コーポレイション 抗ｍｄｌ−１抗体
US8574849B2 (en) 2007-10-03 2013-11-05 The University Of Vermont And State Agriculture College Methods of detection of factor XIa and tissue factor
CA2705851C (en) * 2007-11-21 2016-11-01 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
WO2009154461A1 (en) * 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
CA2743864A1 (en) 2008-11-25 2010-06-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
AU2009335643B2 (en) * 2008-12-18 2014-05-29 Oregon Health & Science University Anti-fXI antibodies and methods of use
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
UA107112C2 (uk) 2010-05-27 2014-11-25 Мерк Шарп Енд Доме Корп. Активатори розчинної гуанілатциклази
CA2803688A1 (en) 2010-06-25 2011-12-29 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
EP2590979A1 (de) 2010-07-09 2013-05-15 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
US20140171434A1 (en) 2011-01-11 2014-06-19 Bayer Pharma Aktiengessellschaft Substituted imidazopyridines and imidazopyridazines and the use thereof
WO2012143510A1 (de) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Fluoralkyl-substituierte pyrazolopyridine und ihre verwendung
WO2013030138A1 (en) 2011-09-01 2013-03-07 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
BR112014005110A2 (pt) 2011-09-02 2017-04-18 Bayer Ip Gmbh pirimidinas aneladas substituídas e utilização das mesmas
US9783614B2 (en) * 2012-05-10 2017-10-10 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof

Also Published As

Publication number Publication date
BR112014027952B1 (pt) 2022-06-21
AU2018200850B2 (en) 2019-09-19
SG10201609322QA (en) 2017-01-27
PL2847228T3 (pl) 2019-03-29
IL235238A0 (en) 2014-12-31
US10221247B2 (en) 2019-03-05
US20180051093A1 (en) 2018-02-22
MX2014013568A (es) 2014-12-08
EP2847228A1 (en) 2015-03-18
AU2018200850C1 (en) 2020-03-12
HUE040580T2 (hu) 2019-03-28
AU2013258043B2 (en) 2017-11-30
BR112014027952A2 (pt) 2019-07-09
EP2847228B1 (en) 2018-07-25
JP2015517305A (ja) 2015-06-22
US20180112009A1 (en) 2018-04-26
CN104684932A (zh) 2015-06-03
US20150099298A1 (en) 2015-04-09
SG11201406719UA (en) 2014-11-27
TW201400504A (zh) 2014-01-01
TWI644925B (zh) 2018-12-21
US9783614B2 (en) 2017-10-10
DK2847228T3 (en) 2018-11-19
WO2013167669A1 (en) 2013-11-14
AU2013258043A1 (en) 2014-11-13
TW201811834A (zh) 2018-04-01
EP3404045A1 (en) 2018-11-21
RS57889B1 (sr) 2019-01-31
TWI631140B (zh) 2018-08-01
MX362454B (es) 2019-01-18
US11046783B2 (en) 2021-06-29
CA2872926A1 (en) 2013-11-14
CA2872926C (en) 2022-07-05
LT2847228T (lt) 2018-11-12
KR20150008166A (ko) 2015-01-21
CN104684932B (zh) 2019-03-12
SI2847228T1 (sl) 2018-11-30
US10040866B2 (en) 2018-08-07
ES2698950T3 (es) 2019-02-06
NZ701121A (en) 2017-06-30
AR091024A1 (es) 2014-12-30
IL235238B (en) 2019-08-29
HK1207091A1 (en) 2016-01-22
ZA201407784B (en) 2019-01-30
AU2018200850A1 (en) 2018-02-22
US20190284300A1 (en) 2019-09-19
KR102060376B1 (ko) 2019-12-30
JP2018148920A (ja) 2018-09-27
HRP20181680T1 (hr) 2018-12-14

Similar Documents

Publication Publication Date Title
US11046783B2 (en) Antibodies capable of binding to the coagulation factor XIa and uses thereof
CN114316061B (zh) 针对血浆激肽释放酶和因子xii的双特异性抗体
JP7753301B2 (ja) 第ＸＩＩａ因子のモノクローナル抗体阻害剤
AU2017236063B2 (en) Monoclonal antibodies against the active site of factor XI and uses thereof
US10266607B2 (en) Antibody binding to TFPI and composition comprising the same
EA036395B1 (ru) Антитела к фактору xi и способы их применения
HK1207091B (en) Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
TR201815476T4 (tr) Koagülasyon Faktörü XI ve/veya bunun aktive formu faktör XIa'ya bağlanabilen antikorlar ve bunların kullanımları.
HK40096491A (en) A monoclonal antibody inhibitor of factor xiia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170321

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180413

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180508

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180601

R150 Certificate of patent or registration of utility model

Ref document number: 6348900

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250